Pain Point, Solved 4.9 ★★★★★ Google Rating

How Do Spravato Clinics Manage Buy-and-Bill Cash Flow So Denied Claims Do Not Turn Drug Inventory Into Losses?

All Pain Points

Ask AI about this page

Spravato clinics protect buy-and-bill cash flow by moving the coverage decision to before the dose, not after, because once the drug is administered a denial is an unrecoverable loss, not a claim to rework. In buy-and-bill the clinic carries the acquisition, inventory, and reimbursement risk: each dose is a four-figure drug cost committed the moment it goes into the patient, and slow payers stretch the float in between. The fix has four moves: confirm active coverage and authorization before every single administration, screen each session for denial risk so a lapsed or terminated plan is caught before you dose, track drug reimbursement by dose so a stuck claim surfaces immediately, and follow up aggressively on aging drug lines before the money is truly gone. We run those moves inside the systems you already use, so a denial after administration becomes the rare exception instead of a monthly write-off. The table of contents maps the whole method; the moves after it are the detail.

How to Keep a Denied Spravato Dose From Becoming a Write-Off
Key Pain Points and Discussions by Providers
Why This Keeps Happening
The Solution
How We Permanently Fix the Process
The Whole Thing in Four Sentences
Frequently Asked Questions
Where the Claims on This Page Come From

How to Keep a Denied Spravato Dose From Becoming a Write-Off

The goal is that no dose goes into a patient until coverage is confirmed, and every dose that is administered gets paid. Here is what does that, move by move.

1. Confirm Active Coverage and Authorization Before Every Dose

The whole model turns on one rule: never administer on an assumption. Before each session, confirm the patient’s coverage is active that day, the prior authorization is still valid, and the plan has not terminated or changed. A coverage that was good at induction can lapse mid-course, and in buy-and-bill that lapse only becomes visible after you have dosed, when it is too late. A same-day eligibility and authorization check before administration is the single cheapest thing that prevents the most expensive loss.

2. Screen Every Session for Denial Risk Before You Commit the Drug

Not every risk is a hard termination. A screen before dosing catches the softer ones too: an authorization about to expire, a session count approaching the plan’s limit, a benefit change at the plan year, a secondary that needs coordination. Flagging those before the vial is opened means the session can be rescheduled, the authorization renewed, or the coverage question resolved while the drug is still inventory, not a sunk cost sitting in a patient. Screening is how you turn a would-be write-off back into a billable session.

3. Track Drug Reimbursement by Dose, Not by Batch

Because the drug is the expensive part of every session, it needs its own tracking. A dose-level tracker follows each administration to its payment: which 56 mg and 84 mg sessions were dosed, which drug lines paid, and which are aging. When a drug line stalls, it shows up immediately as a specific dollar amount tied to a specific dose, not buried in a batch that looks fine in aggregate. That visibility is what keeps a slow payer from quietly stretching your float into a cash crunch.

4. Follow Up Aggressively on Aging Drug Lines Before the Money Is Gone

A stuck drug line is only a permanent loss if it ages out. The moment a dose’s reimbursement stalls, it goes into active follow-up: the reason worked, the claim corrected and resubmitted, the appeal filed before the filing window closes. Because each Spravato dose is four figures, one aged-out drug line is real money, and the difference between recovering it and writing it off is whether someone owned the follow-up while the clock still allowed it. Aggressive, dated follow-up is how administered doses become collected revenue.

5. Hand Buy-and-Bill Protection to a Dedicated Team

Clinics that stop losing drug to denials do it by handing buy-and-bill protection to a dedicated team: remote specialists who confirm coverage before every dose, screen for denial risk, track reimbursement by dose, and work the aging lines, live in 1 to 2 weeks. The providers go back to treating patients, a trained backup covers every gap, and the drug float stops being a bet nobody is watching. Below is what it sounds like when nobody owns this yet, in providers’ own words.

Key Pain Points and Discussions by Providers

real reports from practice staff, lightly edited

“We inducted five patients in one month and were floating something like forty thousand dollars in Spravato before a single claim paid. One patient’s coverage had terminated mid-month and nobody caught it. Four doses in, roughly five thousand dollars of drug we can never bill. That came straight off the bottom line.” – practice administrator, Spravato treatment center

“The thing people do not get about buy-and-bill is that a denial after you dose is not a denial you can rework. The drug is in the patient. There is no vial to return. It is just a loss, and it only shows up after the money is already spent.” – finance lead, interventional psychiatry group

“We were confirming coverage at induction and then just assuming it held for the whole course. It does not. Plans lapse, authorizations expire, benefits change at the plan year, and we found all of that out the expensive way, after the dose.” – revenue cycle manager, behavioral health clinic

“Slow payers are the quiet killer. Even the claims that eventually pay stretch our float for weeks, and when you are buying drug for a full panel of patients, that gap is real cash flow pressure. We needed the drug reimbursement tracked dose by dose, not lumped in a batch.” – billing lead, psychiatry practice

“I made it a hard rule: no dose without a same-day eligibility and authorization check. It felt like overkill until the first time it caught a terminated plan before we opened the vial. That one catch paid for the whole process.” – clinical operations manager, Spravato clinic

Our Answer

Here is what we actually do. A dedicated remote specialist protects the drug float by moving the coverage decision in front of the dose: before every administration they confirm the patient’s coverage is active that day, the authorization is still valid, and nothing has terminated or changed, and they screen each session for the softer denial risks, an expiring auth, a session limit approaching, a plan-year benefit change. They track drug reimbursement dose by dose so a stuck line surfaces immediately, and they work aging drug lines aggressively before the filing window closes. Our specialists are credentialed professionals, overseas-trained physicians and US-licensed nurses and pharmacists, working inside your EHR, billing system, and payer portals, with AI drafting the first-pass eligibility and claim checks and a human verifying before any dose is cleared. This is our insurance eligibility verification and revenue cycle support built for buy-and-bill, in one paragraph.

Why This Keeps Happening

If the model is known, why do clinics still eat drug losses? Because buy-and-bill puts every category of risk on the clinic. You purchase the drug, carry it as inventory, and only get reimbursed after you administer and bill, so acquisition risk, inventory risk, and reimbursement risk all sit with you. Each dose is a four-figure commitment, the 56 mg and 84 mg sessions each represent significant drug cost, and once it is administered there is no return. A denial that would be an annoyance in a fee-for-service visit is a hard loss here, because you already spent the money on the drug that is now in the patient.

Timing is the second half. The risk is highest at the exact moment coverage is least likely to be re-checked: the individual session. Clinics confirm coverage at induction and then assume it holds across a multi-week course, but plans lapse, authorizations expire, session limits are hit, and benefits reset at the plan year. In buy-and-bill, any of those becomes visible only after the dose, when the loss is already booked. Moving a real eligibility and authorization check in front of every administration is exactly what a disciplined benefits verification workflow is built to do.

And slow payers compound it even when nothing denies. Because the drug is the most expensive part of the session and the clinic fronts it, every week a payer takes to reimburse stretches the float, and a clinic inducting a full panel can be carrying tens of thousands in drug at once. That is not a hypothetical; it is ordinary cash flow pressure that a busy Spravato program lives with. Tracking drug reimbursement dose by dose and working the aging lines is what keeps a manageable float from turning into a crunch. That is where dedicated revenue cycle management earns its keep.

⚠️ The quiet one that hurts most: The quiet one that hurts most: the coverage that lapsed after induction. You verified at the start of the course and assumed it held, so you kept dosing. The plan terminated or the authorization expired somewhere in the middle, and you did not see it because nobody re-checked before each session. In fee-for-service that is a denial to appeal. In buy-and-bill it is drug already in the patient with no way to bill it, a pure loss booked the moment you dosed. Unless someone confirms active coverage before every single administration, the most expensive losses are the ones that were preventable with a check you skipped.

Most groups have already tried the obvious fixes before they talk to anyone. Each one fails the same way: the work lands back on the practice. The pattern, in one table:

What you tried	What actually happened	Who ended up doing the work
Verified coverage at induction and assumed it held	Plans lapsed and auths expired mid-course; the loss surfaced only after the dose	An assumption that stopped being true
Treated the drug float like normal accounts receivable	Slow payers stretched the float into cash flow pressure while doses aged unwatched	A batch view that hid the aging
Handled denied drug lines the same as any denial	The dose was already administered, so there was nothing to rework, only a write-off	Nobody, because there was no vial to return
Gave buy-and-bill protection to a dedicated remote specialist	Coverage confirmed before every dose, risk screened, reimbursement tracked by dose, aging lines worked	Someone whose whole job it is

The Solution

So what does “someone whose whole job it is” look like in a buy-and-bill program? The specialist puts a hard gate in front of every dose: a same-day check that the patient’s coverage is active, the authorization is valid, and nothing has terminated or changed since the last session. That single gate catches the terminated plan while the vial is still in inventory, when it is a rescheduled session instead of a five-thousand-dollar loss. Moving that check in front of administration is exactly what dedicated insurance eligibility verification is built to do, and it is the cheapest insurance a buy-and-bill clinic can buy.

Then the specialist screens each session for the softer risks, an expiring authorization, a session count nearing the plan’s cap, a plan-year benefit change, a secondary that needs coordination, so those are resolved before the drug is committed rather than discovered after. And they track drug reimbursement dose by dose, so a stuck line shows up immediately as a specific dollar amount, and they work the aging lines aggressively before the filing window closes. A denial after administration becomes the rare exception, and a slow payer no longer quietly stretches the float into a crunch.

Behind all of it, AI drafts the first-pass eligibility and claim checks and a credentialed human verifies. The workflow re-checks coverage before each dose, flags the denial risks, and surfaces aging drug lines; a person confirms coverage is truly active before a dose is cleared and owns the follow-up on every stuck line. Every security control that protects the chart and coverage data moving through that process is documented and auditable, and the whole approach is described on our HIPAA and security page, because moving clinical and benefit information through a verification workflow is only safe when the controls are real.

Who Actually Does This Work

Fair question: why would an outsourced team protect your drug float better than your own staff? Because re-checking coverage before every dose and tracking drug reimbursement to the dollar is their entire day, not the thing they squeeze in before the patient arrives. The people protecting your buy-and-bill are credentialed medical professionals: overseas-trained physicians, US-licensed nurses and pharmacists, and PharmDs, all trained in US benefits verification and revenue cycle workflows. They know that a coverage confirmed at induction can lapse mid-course, how to catch a terminated plan before the dose, and how to work an aging drug line before it ages out. That is not a task for whoever has a free minute; it is a specialty.

We are not a call center. We are a clinical operations partner, a healthcare BPO built on dedicated virtual staff: 500+ credentialed professionals, 24/7 coverage, and the AI-first-pass plus human-verify workflow you just read about behind every one of them. A typical clinic is live in 1 to 2 weeks, at up to 70% below the cost of hiring locally, and no one on our side goes out without a trained backup already inside your workflow, so a dose never gets administered on stale coverage because the one person who verifies is on vacation.

And the security piece your compliance officer will ask about: we are audited to SOC 2 Type II with zero exceptions and certified for ISO/IEC 27001:2022, HIPAA, and GDPR, with zero breaches in eight years. Every workstation runs inside a secure enclave on US-based servers, with screen captures and downloads blocked by policy, so PHI never sits on someone’s home laptop. Every client account carries a $5M E&O and cyber liability policy and a BAA signed before any work starts; the full detail lives in our HIPAA and security posture.

Put the routine and the people together, and a specific list of things simply stops happening.

✓ What stops happening: What stops happening: the coverage that lapsed after induction and turned four doses into a write-off. The drug float treated like ordinary accounts receivable while slow payers stretched it into a crunch. The denial handled like any other, until someone remembered the drug was already in the patient. The plan-year benefit change nobody screened for. The tens of thousands in drug committed on the assumption that coverage confirmed at the start of a course still holds in the middle.

2-Week Free Trial

Ready to Protect Your Spravato Drug Float?

Book A Strategy Call Request Information

How We Permanently Fix the Process

A person alone is not the fix, and neither is a rule alone. The fix is a documented buy-and-bill workflow: the pre-dose coverage and authorization gate, the denial-risk screen, the dose-level reimbursement tracker, and the aging follow-up standard, all written down and worked the same way before every administration. Before we take a single session for a new clinic, we map your induction and dosing schedule against your payers so we can see exactly where a lapse would bite, and we build the workflow against that, not against a generic template.

From there the workflow becomes a living playbook rather than one manager’s rule of thumb. It records how coverage is re-checked before each dose, which risks the screen catches, how drug reimbursement is tracked dose by dose, and the follow-up cadence that works an aging line before it ages out. It is written down, kept current as payer rules and plan years change, and owned by the team. When your specialist is out, a trained backup works the same playbook the same way, so a dose is never administered on stale coverage because one person was away.

That is the difference between absorbing this month’s drug losses and fixing the process for good, and it is what a dedicated revenue cycle management partner actually buys you. A staffer leaving used to mean coverage stopped getting re-checked and a lapsed plan turned into a write-off. Under this model the gate stays in place, the playbook stays, the backup steps in, and a denied Spravato dose stops being the loss that quietly eats your margin.

The Whole Thing in Four Sentences

Spravato clinics lose drug to denials because buy-and-bill puts acquisition, inventory, and reimbursement risk on the clinic: each four-figure dose is committed the moment it goes into the patient, and once administered a denial is an unrecoverable loss, not a claim to rework. Verifying only at induction, treating the drug float like ordinary receivables, or handling a denied dose like any other denial all fail the same way. The fix is to confirm active coverage before every dose, screen each session for denial risk before committing the drug, track reimbursement dose by dose, and work aging drug lines before the money is gone. An interventional psychiatry group running Spravato uses exactly this model with us today, names withheld, no patient data shown.

If you want to check us out before talking to anyone: our security posture is independently auditable, we are an MGMA 2026 Corporate Member, and 800+ providers run back office work with us.

Ready to protect your Spravato drug float? Try us risk free: two weeks, your real induction and dosing schedule, dedicated specialists confirming coverage before every dose and working the aging lines, and if it does not earn the handoff, you walk away. From here down is the sales part, and it is short: here is exactly what it costs.

Transparent Weekly Pricing

One Flat Weekly Rate. 45 Hours of Coverage.

No hourly meters, no setup fees, no long-term contracts. Your dedicated team member covers your desk 45 hours every week, and a trained backup steps in at no charge whenever they are out.

Single

$399/ week

One dedicated remote specialist confirming coverage before every dose and tracking drug reimbursement end to end, single-site Spravato treatment center

Protect Every Spravato Dose This Month

You have seen the whole method. The pilot proves it on your own induction schedule, with a tracker your team can watch every day.

Start My 2-Week Free Trial

Request Information or call directly: (800) 489-5877

Request Information

Single specialty or multi-site? One payer or many? Tell us your situation and we will map the right coverage within 24 hours.

Frequently Asked Questions

Why does a denied Spravato claim become a loss instead of a reworkable denial?

Because in buy-and-bill the clinic purchases the drug and administers it before reimbursement, so once the dose goes into the patient there is no vial to return. A denial in a normal fee-for-service visit is a claim to appeal; a denial after a Spravato administration is drug already spent with no way to recover it. Each dose is a four-figure drug cost, so a single denied dose after administration lands as a hard write-off, which is why the coverage decision has to happen before the dose, not after.

How do we keep a lapsed plan from turning into a write-off mid-course?

Re-check coverage before every single administration, not just at induction. A plan that was active when the patient started can terminate, an authorization can expire, a session limit can be hit, and benefits can reset at the plan year, all mid-course. A same-day eligibility and authorization check before each dose catches those while the drug is still inventory, so the session is rescheduled or the authorization renewed instead of a dose administered on coverage that no longer exists.

How do we manage the cash flow float from buying Spravato?

Track drug reimbursement dose by dose rather than in a batch, and work aging lines aggressively. Because the clinic fronts the drug cost and the drug is the expensive part of the session, even claims that eventually pay stretch the float for weeks, and a clinic inducting a full panel can carry tens of thousands in drug at once. A dose-level tracker shows exactly which administrations have paid and which are aging, so a slow payer surfaces immediately instead of quietly turning a manageable float into a cash crunch.

What denial risks should we screen for before dosing?

Beyond a hard coverage termination, screen for an authorization about to expire, a session count approaching the plan’s limit, a benefit change at the plan year, and a secondary payer that needs coordination. Any of these can turn an administered dose into a loss if it is missed. Catching them before the vial is opened means the session can be rescheduled or the coverage question resolved while the drug is still inventory, which is what turns a would-be write-off back into a billable session.

How much does outsourced buy-and-bill protection cost?

Staffingly charges a flat weekly rate per dedicated remote specialist, with lower per-person rates for teams of 5 or more and 10 or more. Every plan covers 45 hours of coverage per week with a trained backup included, and there is no percentage of your collections. The pricing section on this page shows how the flat rate compares with typical US market rates for this work.

Will AI be deciding whether we can dose a patient?

No. AI drafts the first-pass eligibility and claim checks, re-checking coverage before each dose, flagging denial risks, and surfacing aging drug lines, and a credentialed human verifies that coverage is truly active before a dose is cleared and owns the follow-up on every stuck line. The decision to dose stays with your clinical team, supported by a verified coverage answer. Automation removes the repetitive re-checking so the specialist spends their time on the cases that need a human.

Do we have to change our EHR or billing system?

No. Our specialists work inside the EHR, billing system, and payer portals you already use, so there is no migration and no new platform for your staff to learn. They verify coverage and track reimbursement where your work already lives, which is why a typical clinic is live in 1 to 2 weeks rather than months.

How fast will we stop losing drug to denials?

Usually within the first two weeks. Once a dedicated specialist is confirming active coverage before every dose, screening each session for denial risk, and tracking drug reimbursement dose by dose, the terminated plans and expired authorizations that used to surface after the dose start getting caught before it, and the aging drug lines that used to be written off start getting worked before the filing window closes.

How does one flat weekly rate cover 45 hours every week?

Your dedicated specialist works a 9-hour day, Monday to Friday, which is 45 hours of coverage each week. The ninth hour is part of the flat weekly rate, not billed as overtime. Over a year that is 2,340 hours of coverage, against the standard US full-time work year of 2,080 hours (40 hours x 52 weeks, the same basis the U.S. Office of Personnel Management uses to compute hourly rates of pay). That is how $399 per week works out to $8.87 per hour.

Written By

Dan Nandan

Founder and CEO, Staffingly, Inc. · Piscataway, NJ

Dan Nandan has spent 25+ years in IT consulting and healthcare BPO, was among the first in the US to build an RPO/BPO delivery network in India, and has been featured in Computerworld. He runs the operations and the dedicated virtual teams behind the workflows on this page; the team-voice answers above come from the remote specialists who work them every day.

Connect on LinkedIn

Where the Claims on This Page Come From

Sources & References

Centers for Medicare and Medicaid Services, Esketamine Billing and Coding Article. CMS guidance on Spravato session billing, coverage rules, and the bundled drug component relevant to buy-and-bill reimbursement. cms.gov
US Food and Drug Administration, Spravato Prescribing Information. Dosing information for the 56 mg and 84 mg esketamine sessions that drive per-dose drug cost in a buy-and-bill model. accessdata.fda.gov
HFMA Revenue Cycle and Cash Flow Resources. Guidance on drug acquisition cost, buy-and-bill reimbursement risk, and denial-driven write-offs for provider-administered drugs. hfma.org
MGMA Practice Operations and Revenue Cycle Resources. Benchmarks and guidance on eligibility verification, authorization, and cash flow management for medical group practices. mgma.com
American Medical Association Prior Authorization and Practice Management Resources. Physician-practice references on authorization, benefits verification, and the administrative burden tied to provider-administered drugs. ama-assn.org